Recent Updates
Recently added Catalysts

Achondroplasia: 4 biotech companies with clinical-stage programmes

Rare Genetic & MetabolicConcentrated betData as of 2026-09-04

Competitors4in the clinic
Median market cap$13.8Buniverse median $1.20B
Allocated capital$18.8B$45.9B competing
Phase 3 or filed13 mid, 0 early
Pure plays0this indication only
Capital rank3/299crowding rank 40

Achondroplasia is a concentrated bet: only 4 US-listed developers are in the clinic, and the median one is worth $13.8B against a $1.20B universe median.

Scarcity is doing the work in that number. A thin field means an approval is shared with fewer rivals, and the market pays a premium for that position.

1 of the 4 is in Phase 3 or filed, and 3 dated catalysts fall in the next 12 months, so this ranking is likely to move.

$18.8B of allocated capital sits in Achondroplasia, ranking it 3rd of 299 indications by the money committed to it.

Companies developing drugs for Achondroplasia 4

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
BMRNBioMarin PharmaceuticalvosoritidePhase 39$12.9BNo5No dated event
ASNDAscendis PharmaCombination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injectionsPhase 24$16.8BNo2 1 Dec 2026
BBIOBridgeBio PharmaInfigratinibPhase 25$14.7BNo2 27 Nov 2026
TYRATyra BioscienceTYRA-300Phase 21$1.5BNo3 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. ASND holds 37% of the $45.9B competing in this indication.

Why Achondroplasia is a concentrated bet

Few competitors, each one large. The market pays a scarcity premium to compete here.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Achondroplasia has 4 competitors and a median of $13.8B.

Rare Genetic & Metabolic

Rare Genetic & Metabolic holds $103B of the map's capital, 15.3% of the total, spread across 32 indications and 48 companies. 10 of those indications have more than one company competing.

See every Rare Genetic & Metabolic indication on the map

Related indications in Rare Genetic & Metabolic

Duchenne Muscular Dystrophy13 companies · $12.8B · median $607MKnife fightPrader-Willi Syndrome4 companies · $10.7B · median $3.6BConcentrated betTurner Syndrome1 company · $8.4B · median $16.8BUncontestedHereditary Angioedema5 companies · $8.3B · median $2.6BConcentrated betAlpha-1 Antitrypsin Deficiency5 companies · $7.6B · median $3.0BConcentrated betPhenylketonuria4 companies · $5.6B · median $4.0BConcentrated betSickle Cell Disease6 companies · $4.8B · median $2.5BGold rushPIK3CA-related Overgrowth Spectrum1 company · $4.2B · median $4.2BUncontested

Achondroplasia pipeline questions

Which biotech companies are developing drugs for Achondroplasia?

BioMarin Pharmaceutical (BMRN, vosoritide, Phase 3); Ascendis Pharma (ASND, Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections, Phase 2); BridgeBio Pharma (BBIO, Infigratinib, Phase 2); Tyra Bioscience (TYRA, TYRA-300, Phase 2). Those are the 4 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Achondroplasia.

How advanced is the Achondroplasia pipeline?

Of the 4 clinical-stage programmes in Achondroplasia, 1 is in Phase 3 or filed, 3 are in mid-stage development and 0 are in early-stage development.

How much is the typical Achondroplasia biotech company worth?

The median company developing a drug for Achondroplasia is worth $13.8B, against a median of $1.20B across the whole universe. $18.8B of allocated capital sits in the indication, ranking it 3rd of 299.

When is the next Achondroplasia catalyst?

The next dated catalyst in Achondroplasia is BBIO on 27 Nov 2026. 3 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map